Salveen Richter
Showing 1–3 of 3 transcripts.
- Goldman Sachs10 min
Biopharma opportunities and macro challenges: A check-up on the industry
Asad Haider, Chris Shibutani, Salveen Richter, Sylvain
Major pharmaceutical and biotech leaders converged to identify GLP-1 agonists and AI integration as primary drivers for a market revised upward to $130 billion, while strategically addressing patent cliffs through aggressive external collaborations and M&A targeting metabolic and neurology assets. Although the biotech IPO window has reopened with nine clinical-stage offerings, investor sentiment remains sensitive to interest rate trajectories and the need for immediate commercial validation of AI-driven discoveries. Consequently, industry capital allocation prioritizes balancing near-term revenue generators with long-term growth catalysts to navigate complex clinical challenges in the central nervous system and cardiovascular disease sectors.
- Goldman Sachs18 min
Gene Editing: The Future of Genomic Medicine & Biotech Investing
Salveen Richter, Allison Nathan, Selvine Richter
Gene editing distinguishes itself from traditional gene therapy by utilizing molecular scissors like CRISPR-Cas9 to permanently correct genetic defects in liver, eye, and neurological applications, with recent ex vivo successes for sickle cell disease and the first in vivo proof-of-concept for TTR. As two CRISPR-based therapies approach regulatory filings in 2022 and pivotal studies advance for rare diseases, the industry faces rigorous FDA safety mandates requiring fifteen years of follow-up data alongside complex reimbursement challenges stemming from the high one-time cost of curative treatments. While significant venture capital and pharmaceutical acquisitions drive the integration of next-generation tools like base and prime editing, the field maintains a strict consensus against germline modifications to mitigate ethical concerns and long-term safety risks.
- Goldman Sachs1h 4m
Dr. Michael Mina of the Harvard T.H. Chan School of Public Health
Michael Mina, Salveen Richter, Terence Flynn, Solving Richter
Dr. Mina outlines the novel coronavirus as a highly transmissible pathogen with reduced virulence that threatens global pandemic spread through widespread asymptomatic transmission and unstable immunity patterns. Current U.S. diagnostics face critical supply chain bottlenecks that necessitate triage-based testing, while therapeutic strategies rely on supportive care and experimental antivirals like Remdesivir alongside accelerating vaccine development. The speaker predicts that aggressive social distancing can suppress transmission to protect healthcare capacity, though long-term management will likely require balancing economic needs with endemic cycles rather than aiming for total eradication.